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Introduction  
 
Worldwide, 181 countries have ratified the WHO’s Framework Convention on Tobacco Control and 
become Parties to the convention,1 and 1.5 billion people in 55 countries are now protected by 
comprehensive smoke-free legislation.2 Smoke-free legislation has been associated with many health 
benefits but the most extensively researched has been myocardial infarction. Thirty one studies, 
covering legislation in 47 jurisdictions, produced a pooled relative risk reduction of 12%.3 Many 
employed simple before and after comparisons, and most had follow-up to only 1-2 years following 
legislation.   
 
In Scotland, the Smoking, Health and Social Care Act prohibited smoking in all enclosed public and 
work places from March 2006. There was a 17% reduction in myocardial infarctions in the year 
following implementation; compared with a 4% decline in England where legislation had not been 
introduced.4 The primary aim was to protect non-smokers from the harmful effects of secondhand 
smoke. However, the legislation was associated with a short-term increase in quit attempts and 
temporary reduction in smoking prevalence.5 Hence, in the year following legislation, myocardial 
infarctions fell among current as well as non-smokers,4 and it is not known whether the overall 
reduction in myocardial infarctions has been maintained long-term. This study uses interrupted time 
series analysis to investigate whether myocardial infarction incidence over the ten years following 
Scottish legislation differed from the underlying trend prior to legislation. 
 
Methods 
 
Because of the sensitive nature of the data and our access agreement with the data provider, requests 
to access the dataset, from researchers training in information governance, should be sent directly to 
eDRIS at NSS.Edris@nhs.net. Use of anonymised extracts of Scottish routine data for health research 
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is covered by generic NHS ethics approval (East of Scotland Research Ethics Committee; reference 
16/ES/0112) We used two Scotland-wide databases to ascertain incident myocardial infarctions in 
Scotland between 2000 and 2016 inclusive. The Scottish Morbidity Record 01 (SMR01) collects data 
on all admissions to Scottish hospitals including date and diagnosis. Death certificates record date and 
cause of death. Both systems use the International Classification of Diseases (ICD). We defined 
myocardial infarction as ICD9 410 or ICD10 I21. In order to include only incident cases, we linked 
admissions and deaths to previous SMR01 records between 1990 and 2016 and excluded any that 
were preceded by an admission for myocardial infarction in the previous ten years.  
 
We derived age-, sex-stratified counts of myocardial infarction by month over the study period. 
Estimates of mid-year population were obtained from the National Records of Scotland website 
(https://www.nrscotland.gov.uk/statistics-and-data/statistics/statistics-by-
theme/population/population-estimates/mid-year-population-estimates) and linear interpolation 
and extrapolation applied to provide monthly population counts stratified by age and sex. The 
myocardial infarction and population counts were combined to derive monthly incidence of 
myocardial infarction per 100,000 population for those <60 and ≥60 years of age. All monthly rates 
were standardised to a common month length using: (myocardial infarction count x 100,000 x 365.25) 
/ (population x 12 x days in month).  
 
We used an interrupted time series design and tested three models: step change only; slope change 
only; and step change followed by slope change. The best model was chosen based on minimising the 
Akaike Information Criterion (AIC) and Bayesian Information Criterion (BIC) statistics. All models were 
estimated using the natural log of incidence and coefficients converted to percentages using: 
100*(exp(β)-1).  
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Introduction of high sensitivity troponin assays during the post legislation period lowered the 
diagnostic threshold for myocardial infarction; producing an artefactual increase in incidence. To take 
account of this, we included a second step and slope change in the model. The new assay was 
introduced into clinical practice in Scotland across 2010, with the exact data varying by hospital.6 To 
identify the most appropriate date, we subjected the monthly data to a series of structural break tests 
using the R and EViews statistical and econometric software packages. To account for autocorrelation 
and heteroskedasticity we used heteroskedasticity and autocorrelation consistent (HAC) Newey West 
standard errors, with a quadratic spectral kernel and automatic bandwidth selection, using the user-
created “ivreg2” routine in Stata. This approach automatically adjusts the variance-covariance matrix 
for seasonality and autocorrelation and results in a more parsimonious model than would be obtained 
if the seasonality and autocorrelation were explicitly modelled using a SARMA (seasonal 
autoregressive moving average) errors model or sine-cosine and monthly dummy variables. Initial data 
cleaning was done using R and the main analyses using Stata v15.1. 
 
Results 
 
Over the 17-year study period (2000-2016), there were 117,161 incident myocardial infarctions: 
84,217 hospitalisations and 32,944 pre-hospital deaths in Scotland (population 5.2 million). Of the 
myocardial infarctions, 27,882 occurred in those <60 years and 89,279 in those ≥60 years. Men 
accounted for 71,144 (60.7%) overall: 21,176 (75.9%) of those <60 years of age and 49,968 (56.0%) of 
those ≥60 years. Among those ≥60 years, the step change model was the best fit (Table 1). The 
implementation of legislation was followed by a 13.41% (95% CI 6.53%, 19.78%) step reduction in 
myocardial infarction incidence overall; slightly lower in men (95% CI -13.17%, 95% CI -19.11%, -6.78%) 
than women (-13.95%, 95% CI -20.94%, -6.33%) but statistically significant in both (Figure 1).  Among 
those aged <60 years, the best fit was a step and slope change model. It only reached statistical 
significance among women who had an 18.28% (95% CI 9.57%, 26.15%) step reduction at the time of 
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legislation, but a subsequent increase in slope of 0.70% (0.44%, 0.97%) relative to the underlying 
trend. 
 
Discussion 
 
Myocardial infarction incidence was declining in Scotland prior to 2006, but there was an additional 
step reduction at the time that smoke-free legislation was implemented in both women and older 
men. The benefit has persisted to ten years follow-up among people aged ≥60 years, but not among 
younger people.  
 
The most recent meta-analysis identified 31 studies; 21 from the Americas; 9 from Europe and 1 from 
New Zealand.3 Together, they covered legislation introduced between 1991 and 2010 in 47 
jurisdictions and produced a pooled reduction of 12%. The majority made simple before and after 
comparisons using up to 1-2 years follow-up. The longest follow-up study applied time-series analysis 
to hospitalisations for myocardial infarction from eight years before to five years after introduction of 
comprehensive smoke-free legislation in Prince Edward Island, Canada (population 143,000), and 
reported a 5.92% step reduction followed by a non-significant 0.07% reduction in slope.7 Inclusion was 
not restricted to incident hospitalisations and pre-hospital deaths were not included.  
 
A strength of our study was the inclusion of all events nationwide; thereby avoiding selection bias. A 
general population of 5.2 million and study population of 117,161 myocardial infarctions, increased 
our power to undertake sub-group analyses. Including both hospital admissions and pre-hospital 
deaths avoided any bias due to temporal changes in clinical practice, severity or prognosis. We 
previously showed secondhand smoke exposure impacts on myocardial infarction survival8 as well as 
incidence. By excluding people who had a myocardial infarction in the previous ten years, we could be 
sure that any change was due to legislation impacting on incidence not prognosis. We used routine 
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data but they are subjected to regular quality assurance checks. Smoking status is not recorded. 
Therefore, we were unable to distinguish between reductions in non-smokers, current smokers or 
both. 
 
As with any natural experiment, extraneous changes and interventions can occur over the study 
period. The introduction of high-sensitivity troponin assays lowered the diagnostic threshold. We 
were able to include this in the model and showed it did not account for all the increase in incidence 
from 2006 in younger people. Lack of data on changes in weather and pollution were a limitation and 
should be included in future studies. However, the most plausible explanation for the recent rise in 
myocardial infarction among younger people is increasing incidence of adiposity and, subsequently, 
type 2 diabetes. Data from the Scottish National Diabetes Register have shown that, between 2004 
and 2013, the incidence of type 2 diabetes remained stable overall but: declined in older men and 
women; remained stable in young women; and increased in young men.9 This pattern may explain our 
finding that legislation has not impacted significantly on younger men and its initial impact in younger 
women has not persisted. This finding suggests that adiposity and type 2 diabetes may now have 
superseded smoking as the major driver of the trend in myocardial infarction among younger patients. 
However, this does not justify complacency in ongoing effects at tobacco control.   
 
 
Sources of funding 
 
No external funding 
 
 
Disclosures 
 
None 
 
 
 
References 
 
 7 
1. WHO. Parties to the WHO Framework Convention on Tobacco Control: WHO [updated July 17, 
2017. Available from: http://www.who.int/fctc/signatories_parties/en (accessed 23/11/2018)  
2. WHO report on the global tobacco epidemic. Monitoring tobacco control and prevention policies. 
Geneva: WHO; 2017. 
https://apps.who.int/iris/bitstream/handle/10665/255874/9789241512824-
eng.pdf;jsessionid=AA10EE020518ADED8EA13B536E034312?sequence=1 (accessed 23/11/2018) 
3. Jones MR, Barnoya J, Stranges S, Losonczy L, Navas-Acien A. Cardiovascular events following 
smoke-free legislations: An updated systematic review and meta-analysis. Curr Environ Health Rep 
2014;1:239-149. 
4. Pell JP, Haw S, Cobbe S, Newby DE, Pell ACH, Fischbacher C, McConnachie A, Pringle S, Murdoch 
D, Dunn F, Oldroyd K, MacIntyre P, O’Rourke B, Borland W. Smoke-free legislation and 
hospitalizations for acute coronary syndrome. New Engl J Med 2008:359:482-91. 
5. Mackay DF, Haw S, Pell JP. Impact of Scottish smoke-free legislation on smoking quit attempts and 
prevalence. PLOS One 2011;6:e26188.  
6. Chapman AR, Newby DE, Mills NL. High-sensitivity cardiac troponin I assays in the diagnosis of 
acute myocardial infarction Heart Asia 2017;9:88-89. doi:10.1136/heartasia-2016-010867 
(accessed 23/11/2018) 
7. Gaudreau K, Sanford CJ, Cheverie C, McClure C. The effect of a smoking ban on hospitalization 
rates for cardiovascular and respiratory conditions in Prince Edward Island, Canada. PLoS One 
2013;8:e56102. doi:10.1371\journal.pone.0056102. 
8. Pell JP, Haw S, Cobbe S, Newby DE, Pell ACH, Fischbacher C, Pringle S, Murdoch D, Dunn F, Oldroyd 
K, MacIntyre P, O’Rourke B, Borland W. Second-hand smoke exposure and survival following acute 
coronary syndrome: Prospective cohort study of 1,261 consecutive admissions among never 
smokers. Heart 2009;95:1415-8.  
9. Read SH, Kerssens JJ, McAllister DA, Colhoun HN, Fischbacher CM, Lindsay RS, McCrimmon RJ, 
McKnight JA, Petrie JR, Sattar N, Wild SH, Scottish Diabetes Research Network Epidemiology 
 8 
Group. Trends in type 2 diabetes incidence and mortality in Scotland between 2004 and 2013. 
Diabetologia 2016;59:2106–2113.  
 
 
 9 
Table 1  Interrupted time series models of the effects of Scottish smoke-free legislation on the incidence of myocardial infarction  
 
 
 
Slope change only 
 
 
Step change only 
 
Step and slope changes 
 Pre legislation slope 
Post legislation 
slope 
AIC 
BIC Step 
AIC 
BIC Step 
Post legislation 
slope 
AIC 
BIC 
 
% 
(95% CI) 
 
P value % (95% CI) P value  
% 
(95% CI) P value  
% 
(95% CI) P value 
% 
(95% CI) P value  
 
>=60 yrs              
    All 
-0.16 
(-0.31, -0.10) 
 
0.037 -0.04 (-0.33, 0.26) 0.802 
-418.8 
-402.6 
-13.41 
(-19,78, -6.53) <0.001 
-448.5 
-432.2 
-13.99 
(-19.22, -8.42) <0.001 
0.07 
(-0.09, 0.24) 0.390 
-447.5 
-428.0 
    Men 
-0.19 
(-0.34, -0.03) 
 
0.017 -0.009 (-0.31, 0.30) 0.955 
-389.1 
372.8 
-13.17 
(-19.11, -6.78) <0.001 
-408.5 
-392.3 
-13.98 
(-19.90, -7.62) <0.001 
0.10 
(0.001, 0.20) 0.047 
-408.1 
-388.6 
    Women 
-0.14 
(-0.29, 0.01) 
 
0.607 -0.08 (-0.39, 0.23) 0.339 
-325.1 
-308.8 
-13.95 
(-20.94, -6.33) 0.001 
-343.9 
-327.6 
-14.20 
(-22.02, -5.60) 0.002 
0.03 
(-0.16, 0.22) 0.740 
-342.0 
-322.5 
<60 yrs              
     All 
-0.08 
(-0.20, 0.04) 
 
0.194 0.22 (-0.015, 0.45) 0.066 
-351.1 
-334.8 
-5.94 
(-15.00, 4.08) 0.236 
-349.0 
-332.7 
-8.37 
(-17.25, 1.47) 0.093 
0.28 
(0.11, 0.46) 0.001 
-355.9 
-336.4 
     Men 
-0.04 
(-0.13, 0.06) 
 
0.433 0.11 (-0.07, 0.28) 0.248 
-324.4 
-308.2 
-4.17 
(-11.19, 3.41) 0.272 
-324.8 
-308.5 
-5.46 
(-12.55, 2.20) 0.158 
0.15 
(-0.06, 0.35) 0.166 
-324.9 
-305.3 
     Women -0.21 (-0.44, 0.02) 0.075 
0.55 
(0.09, 1.02) 0.019 
-89.7 
-73.4 
-12.83 
(-29.01, 7.05) 0.190 
-85.1 
-68.8 
-18.28 
(-26.15, -9.57) <0.001 
0.70 
(0.44, 0.97) <0.001 
-97.1 
-77.5 
                  
 
AIC Akaike Information Criterion; BIC Bayesian Information Criterion; CI confidence interval 
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Figure 1. Monthly Incidence of myocardial infarction over time by age 
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